The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [1] The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease
    Tomoyuki Kawada
    Clinical and Experimental Nephrology, 2016, 20 : 147 - 148
  • [2] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Hannah A. Blair
    Gillian M. Keating
    Drugs, 2015, 75 : 1797 - 1806
  • [3] An update on tolvaptan for autosomal dominant polycystic kidney disease
    Poch, E.
    Rodas, L.
    Blasco, M.
    Molina, A.
    Quintana, L.
    DRUGS OF TODAY, 2018, 54 (09) : 519 - 533
  • [4] Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Baur, Brian P.
    Meaney, Calvin J.
    PHARMACOTHERAPY, 2014, 34 (06): : 605 - 616
  • [5] Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
    Shigeo Horie
    Satoru Muto
    Haruna Kawano
    Tadashi Okada
    Yoshiyuki Shibasaki
    Koji Nakajima
    Tatsuki Ibuki
    Clinical and Experimental Nephrology, 2021, 25 : 467 - 478
  • [6] Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
    Horie, Shigeo
    Muto, Satoru
    Kawano, Haruna
    Okada, Tadashi
    Shibasaki, Yoshiyuki
    Nakajima, Koji
    Ibuki, Tatsuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (05) : 467 - 478
  • [7] Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice
    Hines, Cheryl B.
    Hooper, Gwendolyn L.
    Collins-Yoder, Angela
    NEPHROLOGY NURSING JOURNAL, 2020, 47 (02) : 145 - 150
  • [8] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [9] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Hiroko Iijima
    Toshifumi Tada
    Mariko Hashimoto
    Takashi Nishimura
    Masato Kiriki
    Akiko Higashiura
    Aya Iwasaki
    Michino Honda
    Yasuyuki Nagasawa
    Koichiro Yamakado
    Journal of Medical Ultrasonics, 2023, 50 : 81 - 87
  • [10] Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
    Masahiko Oguro
    Yuta Kogure
    Junichi Hoshino
    Yoshifumi Ubara
    Hiroki Mizuno
    Akinari Sekine
    Masahiro Kawada
    Keiichi Sumida
    Rikako Hiramatsu
    Eiko Hasegawa
    Masayuki Yamanouchi
    Noriko Hayami
    Tatsuya Suwabe
    Naoki Sawa
    Kenmei Takaichi
    Journal of Nephrology, 2018, 31 : 961 - 966
12345